John Theurer Cancer Center Researchers Share 46 Cutting Edge Studies at 2017 ASH Meeting

Published: Saturday, Dec 09, 2017

Researchers from the Hackensack Merdian Health John Theurer Cancer Center at Hackensack University Medical Center will present results from 46 cancer-related studies during the American Society of Hematology (ASH) 59th Annual Meeting, which will take place December 9 – 12, 2017 in Atlanta. The studies examine new cancer treatments, ways to predict the best treatment outcomes, and patient quality of life issues.

“ASH is a great venue for sharing best practices and learning about the latest treatment approaches – we are proud to help contribute by presenting our recent scientific work,” André Goy, MD, MS, chairman and director, division chief of Lymphoma, John Theurer Cancer Center; chief science officer and director of Research and Innovation, RCCA; professor of medicine, Georgetown University. “Our researchers will keep working to improve oncology and help develop some of the newest approaches to treating cancer. This will remain a priority for our cancer center.” Among other promising research, John Theurer Cancer Center investigators will present highlights from studies in mantle cell lymphoma (MCL), stem cell transplantation, CAR T-cell therapy, precision medicine in multiple myeloma (MM), Hodgkin lymphoma and new combinations in blood cancers at the ASH annual meeting.

Novel strategies in mantle cell lymphoma
  • 155 - Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study, Andre Goy, MD et al.. Oral Presentation - Saturday, December 9, 2017: 1:00 PM, Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center)
  • 151 - Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis, Andre Goy, MD et al..Oral Presentation - Saturday, December 9, 2017: 12:00 PM, Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center)
  • 2785 - Phase Ib-II Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma, Andre Goy, MD et al.. Poster Presentation- Sunday, December 10, 2017, 6:00 PM-8:00 PM, Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)


Novel strategies in stem cell transplantation
  • 340 - Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies – Alan Skarbnik, MD, et al.. Oral Presentation CPIT-001 Trial Sunday, December 10, 2017: 8:15 AM, Bldg B, Lvl 4, B401-B402 (Georgia World Congress Center)
  • 1862 - Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma, Poster Presentation, Saturday, December 9, 2017, 5:30 PM-7:30 PM, Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)


CAR T-cell therapy
  • 740 - Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy, Oral Presentation, Monday, December 11, 2017: 3:00 PM, Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)


Precision medicine in multiple myeloma
  • 679 - Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma, Alan Richter, MD et al.., Oral Presentation, Monday, December 11, 2017: 10:30 AM, Bldg C, Lvl 2, C208-C210 (Georgia World Congress Center)
  • 395 - Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol, Oral Presentation, Sunday, December 10, 2017: 10:30 AM Bldg B, Lvl 3, B304-B305 (Georgia World Congress Center)
  • 1831 - A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma, Noa Biran, MD et al.., Poster Presentation, Saturday, December 9, 2017, 5:30 PM-7:30 PM, Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)


Novel therapies and new combinations in Hodgkin Lymphoma
  • 6 - Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study, Plenary Scientific Session, Sunday, December 10, 2017, 2:00 PM-4:00 PM, Bldg C, Lvl 1, Hall C2-C3 (Georgia World Congress Center)
  • 649 - Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma, Oral Presentation, Monday, December 11, 2017: 10:30 AM, Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)
  • 651 - Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study, Oral Presentation, Monday, December 11, 2017: 11:00 AM, Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x